Skip to search formSkip to main contentSkip to account menu

otlertuzumab

A recombinant single-chain polypeptide engineered to exhibit the full binding and activity of an anti-CD37 monoclonal antibody with potential… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Otlertuzumab (TRU‐016) is a humanized anti‐CD37 protein therapeutic that triggers direct caspase‐independent apoptosis of… 
2015
2015
CD37 is cell surface tetraspanin present on normal and malignant B cells. Otlertuzumab (TRU‐016) is a novel humanized anti‐CD37… 
Review
2015
Review
2015
Effective new treatments are now available for patients with hematologic malignancies. However, their propensity to cause tumor… 
Highly Cited
2014
Highly Cited
2014
Otlertuzumab is a novel humanized anti-CD37 protein therapeutic. This study evaluated the safety of otlertuzumab administered… 
2014
2014
SummaryPurpose CD37 is cell surface tetraspanin present on normal and malignant B cells. Otlertuzumab (TRU-016) is a novel… 
2014
2014
Background: CD37 is a tetraspanin protein expressed on the surface of normal and transformed B cells across a wide range of… 
Review
2014
Review
2014
Introduction: Immunotherapy using mAbs is a safe and effective method for the treatment of chronic lymphocytic leukemia (CLL) and… 
2014
2014
In this issue of Blood , Byrd et al present first-in-man data in chronic lymphocytic leukemia (CLL) using otlertuzumab (TRU-016… 
2013
2013
Background CD37 is a tetraspanin protein expressed on the surface of normal and transformed B-cells across a wide range of… 
2013
2013
Background CD37 is a tetraspanin protein expressed on the surface of normal and transformed B-cells across a wide range of…